These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

641 related items for PubMed ID: 28668554

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathways.
    Li Q, Wang C, Wang Y, Sun L, Liu Z, Wang L, Song T, Yao Y, Liu Q, Tu K.
    J Exp Clin Cancer Res; 2018 Sep 19; 37(1):231. PubMed ID: 30231922
    [Abstract] [Full Text] [Related]

  • 3. Periostin involved in the activated hepatic stellate cells-induced progression of residual hepatocellular carcinoma after sublethal heat treatment: its role and potential for therapeutic inhibition.
    Zhang R, Lin XH, Ma M, Chen J, Chen J, Gao DM, Cui JF, Chen RX.
    J Transl Med; 2018 Nov 06; 16(1):302. PubMed ID: 30400797
    [Abstract] [Full Text] [Related]

  • 4. [Hepatic stellate cell conditioned medium induces proliferation and epithelial-mesenchymal transition via activating ERK1/2 signaling pathway in hepatoma cells].
    Xie Y, Liao R, Pan L, Fan K, Peng C, Du C.
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 Feb 06; 33(2):210-4. PubMed ID: 29762991
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. RASSF7 promotes cell proliferation through activating MEK1/2-ERK1/2 signaling pathway in hepatocellular carcinoma.
    Zhang M, Li Q, Zhang L, Wang Y, Wang L, Li Q, He T, Wan B, Wang X.
    Cell Mol Biol (Noisy-le-grand); 2018 Apr 30; 64(5):73-79. PubMed ID: 29729697
    [Abstract] [Full Text] [Related]

  • 7. HOXB7 accelerates the malignant progression of hepatocellular carcinoma by promoting stemness and epithelial-mesenchymal transition.
    Huan HB, Yang DP, Wen XD, Chen XJ, Zhang L, Wu LL, Bie P, Xia F.
    J Exp Clin Cancer Res; 2017 Jun 24; 36(1):86. PubMed ID: 28646927
    [Abstract] [Full Text] [Related]

  • 8. MicroRNA-294 Promotes Cell Proliferation, Migration and Invasion in SMMC-7721 Hepatoma Carcinoma Cells by Activating the JNK/ERK Signaling Pathway.
    Cheng X, Chen M, Liu Z.
    Am J Med Sci; 2020 Jun 24; 359(6):365-371. PubMed ID: 32498943
    [Abstract] [Full Text] [Related]

  • 9. Glypican-3 promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through ERK signaling pathway.
    Wu Y, Liu H, Weng H, Zhang X, Li P, Fan CL, Li B, Dong PL, Li L, Dooley S, Ding HG.
    Int J Oncol; 2015 Mar 24; 46(3):1275-85. PubMed ID: 25572615
    [Abstract] [Full Text] [Related]

  • 10. MCM6 promotes metastasis of hepatocellular carcinoma via MEK/ERK pathway and serves as a novel serum biomarker for early recurrence.
    Liu M, Hu Q, Tu M, Wang X, Yang Z, Yang G, Luo R.
    J Exp Clin Cancer Res; 2018 Jan 22; 37(1):10. PubMed ID: 29357919
    [Abstract] [Full Text] [Related]

  • 11. Importance of activated hepatic stellate cells and angiopoietin-1 in the pathogenesis of hepatocellular carcinoma.
    Lin JZ, Meng LL, Li YZ, Chen SX, Xu JL, Tang YJ, Lin N.
    Mol Med Rep; 2016 Aug 22; 14(2):1721-5. PubMed ID: 27358066
    [Abstract] [Full Text] [Related]

  • 12. lncRNA DRHC inhibits proliferation and invasion in hepatocellular carcinoma via c-Myb-regulated MEK/ERK signaling.
    Zhuang R, Zhang X, Lu D, Wang J, Zhuo J, Wei X, Ling Q, Xie H, Zheng S, Xu X.
    Mol Carcinog; 2019 Mar 22; 58(3):366-375. PubMed ID: 30362626
    [Abstract] [Full Text] [Related]

  • 13. HOXB7 promotes tumor progression via bFGF-induced activation of MAPK/ERK pathway and indicated poor prognosis in hepatocellular carcinoma.
    Wang WM, Xu Y, Wang YH, Sun HX, Sun YF, He YF, Zhu QF, Hu B, Zhang X, Xia JL, Qiu SJ, Zhou J, Yang XR, Fan J.
    Oncotarget; 2017 Jul 18; 8(29):47121-47135. PubMed ID: 28454092
    [Abstract] [Full Text] [Related]

  • 14. Activated hepatic stellate cells promote angiogenesis in hepatocellular carcinoma by secreting angiopoietin-1.
    Lin N, Meng L, Lin J, Chen S, Zhang P, Chen Q, Lin Y.
    J Cell Biochem; 2020 Feb 18; 121(2):1441-1451. PubMed ID: 31609020
    [Abstract] [Full Text] [Related]

  • 15. OTX1 Contributes to Hepatocellular Carcinoma Progression by Regulation of ERK/MAPK Pathway.
    Li H, Miao Q, Xu CW, Huang JH, Zhou YF, Wu MJ.
    J Korean Med Sci; 2016 Aug 18; 31(8):1215-23. PubMed ID: 27478331
    [Abstract] [Full Text] [Related]

  • 16. MicroRNA-451: epithelial-mesenchymal transition inhibitor and prognostic biomarker of hepatocelluar carcinoma.
    Huang JY, Zhang K, Chen DQ, Chen J, Feng B, Song H, Chen Y, Zhu Z, Lu L, De W, Wang R, Chen LB.
    Oncotarget; 2015 Jul 30; 6(21):18613-30. PubMed ID: 26164082
    [Abstract] [Full Text] [Related]

  • 17. Long non-coding RNA UBE2CP3 enhances HCC cell secretion of VEGFA and promotes angiogenesis by activating ERK1/2/HIF-1α/VEGFA signalling in hepatocellular carcinoma.
    Lin J, Cao S, Wang Y, Hu Y, Liu H, Li J, Chen J, Li P, Liu J, Wang Q, Zheng L.
    J Exp Clin Cancer Res; 2018 Jun 04; 37(1):113. PubMed ID: 29866133
    [Abstract] [Full Text] [Related]

  • 18. Serine protease inhibitor Kazal type 1 (SPINK1) downregulates E-cadherin and induces EMT of hepatoma cells to promote hepatocellular carcinoma metastasis via the MEK/ERK signaling pathway.
    Ying HY, Gong CJ, Feng Y, Jing DD, Lu LG.
    J Dig Dis; 2017 Jun 04; 18(6):349-358. PubMed ID: 28544403
    [Abstract] [Full Text] [Related]

  • 19. Chemokine ligand 20 enhances progression of hepatocellular carcinoma via epithelial-mesenchymal transition.
    Hou KZ, Fu ZQ, Gong H.
    World J Gastroenterol; 2015 Jan 14; 21(2):475-83. PubMed ID: 25593462
    [Abstract] [Full Text] [Related]

  • 20. STYK1 promotes epithelial-mesenchymal transition and tumor metastasis in human hepatocellular carcinoma through MEK/ERK and PI3K/AKT signaling.
    Wang Z, Qu L, Deng B, Sun X, Wu S, Liao J, Fan J, Peng Z.
    Sci Rep; 2016 Sep 15; 6():33205. PubMed ID: 27628214
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.